Stay updated with breaking news from Nasdaq Itrm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Iterum Therapeutics (NASDAQ:ITRM – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They presently have a $6.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 277.36% from the stock’s current price. Iterum […]
Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) and RedHill Biopharma (NASDAQ:RDHL – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations. Analyst Ratings This is a breakdown of […]
Iterum Therapeutics plc (NASDAQ:ITRM – Free Report) – HC Wainwright issued their FY2028 EPS estimates for shares of Iterum Therapeutics in a note issued to investors on Wednesday, February 7th. HC Wainwright analyst E. Arce expects that the company will earn $0.16 per share for the year. HC Wainwright currently has a “Buy” rating and […]
Iterum Therapeutics plc (NASDAQ:ITRM – Get Free Report) Director Michael W. Dunne purchased 25,000 shares of the business’s stock in a transaction dated Friday, December 22nd. The shares were purchased at an average price of $1.40 per share, for a total transaction of $35,000.00. Following the acquisition, the director now owns 113,754 shares of the […]
Iterum Therapeutics plc (NASDAQ:ITRM – Get Free Report) Director Michael W. Dunne purchased 20,000 shares of Iterum Therapeutics stock in a transaction on Wednesday, November 22nd. The shares were acquired at an average cost of $2.03 per share, with a total value of $40,600.00. Following the completion of the transaction, the director now directly owns […]